https://www.enterair.pl/slot-gacor/

CHRONIC VIRAL HEPATITIS IN THE REPUBLIC OF KAZAKHSTAN AT THE PRESENT STAGE: FACTORS INFLUENCING THE COURSE AND OUTCOMES, THE ROLE OF METABOLIC SYNDROME

  • A. A. Konysbekova Medical University of Astana
  • K. S. Kaliaskarova Medical University of Astana
  • F. K. Bekenova Medical University of Astana
Keywords: chronic hepatitis B, hepatitis D, chronic hepatitis C, Republic of Kazakhstan, liver fibrosis, steatosis

Abstract

Background. Parenteral viral hepatitis B, C and D are one of the main problems of healthcare worldwide. Objective – to analyze the effect of viral hepatitis in the Republic of Kazakhstan at the present stage. Material and methods. The study used indicators of descriptive statistics of the scientific and practical center "Sanitary and Epidemiological Expertise and Monitoring" of the Committee for the Protection of Consumer Rights of the Ministry of National Economy (MNE) of the Republic of Kazakhstan (RK) and of the Committee for Statistics of the MNE of RK. Results. The introduction of a vaccination against hepatitis B into Vaccination schedule has led to a significant decrease in the incidence of viral hepatitis B among people under 18 years of age in the Republic of Kazakhstan. However, there is an increase in the incidence of delta hepatitis, for example, from 2012 to 2016, the incidence of chronic viral hepatitis B with delta agent in citizens over 18 years old increased by 50% and amounted to 0.57 cases per 100 thousand people. Conclusions. Taking into account the increase in access to highly active antiviral agents in the Republic of Kazakhstan, the paradigm of projected elimination of hepatitis C is presented. The study of hepatic steatosis is becoming relevant, due to the increasing rate of metabolic disorders worldwide, including the Republic of Kazakhstan.

References


1. Vsemirnaja organizacija zdravoohranenija. Gepatit B v Evropejskom regione VOZ [Hepatitis B in the WHO European Region]. Informacionnyj bjulleten (ijul 2015). [Internet]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0006/283452/fact-sheet-ru-hep-b.pdf?ua=1. (Russian).


2. World Health Organization. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2017. [Internet]. Available from: https://www.who.int/immunization/diseases/hepatitisB/HBsAg_estimates_and_methods_final_V3.pdf.


3. Esmembetov KI, Abdurahmanov DT, Odincov AV, Muhin NA. Sovremennye predstavlenija o patogeneze, estestvennom techenii i lechenii gepatita delta (35 let s momenta otkrytija) [Current concepts of pathogenesis, clinical course and treatment of hepatitis delta (35 years since its discovery)]. Klinicheskaja medicina [Clinical Medicine (RussianJournal)]. 2013;91(5):22-26. (Russian).


4. Lopatkina TN, Abdurahmanov DT, Krel PE. Gepatocelljuljarnaja karcinoma i virusy gepatita. Gepatologicheskij forum. 2005;1:20-22. (Russian).


5. World Health Organization. Kazakhstan: WHO statistical profile. [Internet]. Available from: http://www.euro.who.int/en/countries/kazakhstan.


6. Nersesov AV, Berkinbaev SF, Dzhunusbekova GA, Dzhumabaeva AE, Novickaja MS, Kuanysh N. Rasprostranennost virusnyh gepatitov sredi zhitelej Juzhno-Kazahstanskoj oblasti [Prevalence of viral hepatitis among residents of South Kazakhstan Region]. Medicina (Almaty) [Medicine (Almaty)]. 2016;9:30-33. (Russian).


7. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen D-S, van Damme P, Abbas Z, Abdulla M, Rached AA, Adda D, Aho I, Akarca U, Hasan F, Lawati F, Naamani K, Al-Ashgar HI, Alavian SM, Alawadhi S, Albillos A, Al-Busafi SA, Aleman S, Alfaleh FZ, Aljumah AA, Anand AC, Anh NT, Arends JE, … , Konysbekova AA, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 2018;3(6):383-403. https://doi.org/10.1016/S2468-1253(18)30056-6.


8. Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, Al Badri M, Al-Busafi SA, … , Konysbekova AA, et al. Historical epidemiology of hepatitis C virus in select countries-volume 4. J. Viral Hepat. 2017;24(Suppl 2):8-24.https://doi.org/10.1111/jvh.12762.


9. Kaliaskarova KS. Faktory progressirovanija hronicheskih virusnyh gepatitov B, C v korennoj populjacii Kazahstana [master’s thesis] Karaganda (Кazahstan); 2010. 24 p. (Russian).


10. Simakova O, editor. Sbornik materialov proekta Ocenka jeffektivnosti realizacii Programmy “Salamatty Қazaқstan» na pervom jetape (2011-2013)». Almaty: CSPI “Strategija”; 2014. 76 p. (Russian).


11. Pirogova IJu, Pyshkin SA, Efremova EV, Gorfinkel AN, Pogorelova SG, Abramovskaja NV. Diagnosticheskie vozmozhnosti metodov neinvazivnoj ocenki fibroza pri diffuznyh zabolevanijah pecheni. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2009;19(4):48-54. (Russian).


12. Byrne CD, Targher G. NAFLD: A Multisystem Disease. J. Hepatol. 62(1 Suppl):S47-64. https://doi.org/10.1016/j.jhep.2014.12.012.


13. Zhang Z, Thorne JL, Moore JB. Vitamin D and Nonalcoholic Fatty Liver Disease. Curr. Opin. Clin. Nutr. Metab. Care. 2019;22(6):449-458. https://doi.org/10.1097/MCO.0000000000000605.


14. Hoan NX, Tong VH, Song LH, Meyer CG, Velavan TP. Vitamin D deficiency and hepatitis viruses-associated liver diseases: a literature review. World J. Gastroenterol. 2018;24(4):445-460. https://doi.org/10.3748/wjg.v24.i4.445.


15. Pushkarev KA, Kausova GK, Berlizeva JuA, Vasilchenko NV, Kajrat G. Deficit vitamina D kak faktor snizhenija rabotosposobnosti u podrostkov [Vitamin D deficiency as a performance decrement factor in adolescents]. Medicina (Almaty) [Medicine (Almaty)]. 2018;2:34-38. (Russian).


16. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J. Viral Hepat. 2010;17(11):749-756. https://doi.org/10.1111/j.1365-2893.2010.01353.x.


17. Nersеsov AV, Isatullaev EA, Palgova LK, Oshakbayev KP, Kaibullayeva ZhA, Raissova AM, Ashimkhanova A. On the issue of HDV-infection in Kazakhstan. Krov. 2011;2:34.


18. Didenko VI. Sovremennye dostizhenija v ocenke steatoza pecheni [Recent advances in the assessment of hepatic steatosis]. Gastroenterologija [Gastrоenterology]. 2015;3:94-100. (Russian).

Published
2020-06-03
How to Cite
1.
Konysbekova AA, Kaliaskarova KS, Bekenova FK. CHRONIC VIRAL HEPATITIS IN THE REPUBLIC OF KAZAKHSTAN AT THE PRESENT STAGE: FACTORS INFLUENCING THE COURSE AND OUTCOMES, THE ROLE OF METABOLIC SYNDROME. journalHandG [Internet]. 2020Jun.3 [cited 2024May16];4(1):62-7. Available from: http://www.journal-grsmu.by/index.php/journalHandG/article/view/139
Section
Оригинальные исследования
https://cbt20.fk.uns.ac.id/terbaru/https://djpen.kemendag.go.id/papamama/demo/http://ct.if.unsoed.ac.id/menang/